key: cord-0777526-tzmbi9f4
authors: Faulkner, Nikhil; Ng, Kevin W.; Wu, Mary; Harvey, Ruth; Margaritis, Marios; Paraskevopoulou, Stavroula; Houlihan, Catherine F.; Hussain, Saira; Greco, Maria; Bolland, William; Warchal, Scott; Heaney, Judith; Rickman, Hannah; Spyer, Moira J.; Frampton, Daniel; Byott, Matthew; de Oliveira, Tulio; Sigal, Alex; Kjaer, Svend; Swanton, Charles; Gandhi, Sonia; Beale, Rupert; Gamblin, Steve J.; McCauley, John; Daniels, Rodney; Howell, Michael; Bauer, David L.V.; Nastouli, Eleni; Kassiotis, George
title: Reduced antibody cross-reactivity following infection with B.1.1.7 than with parental SARS-CoV-2 strains
date: 2021-03-01
journal: bioRxiv
DOI: 10.1101/2021.03.01.433314
sha: afa86a21cfb2739e72f5b57827a5b43a52aa38e5
doc_id: 777526
cord_uid: tzmbi9f4

We examined the immunogenicity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant B.1.1.7 that arose in the United Kingdom and spread globally. Antibodies elicited by B.1.1.7 infection exhibited significantly reduced recognition and neutralisation of parental strains or of the South Africa B.1.351 variant, than of the infecting variant. The drop in cross-reactivity was more pronounced following B.1.1.7 than parental strain infection, indicating asymmetric heterotypic immunity induced by SARS-CoV-2 variants.

. Such reduction in cross-reactivity also impinges the effectiveness of current vaccines based on the Wuhan strain 4-10 , prompting consideration of alternative vaccines based on the new variants. However, the immunogenicity of the latter or, indeed, the degree of heterotypic immunity the new variants may afford remains unknown.

The B.1.1.7 variant is thought to have first emerged in the UK in September 2020 and has since been detected in over 50 countries 11 . To examine the antibody response to B.1.1.7, we collected sera from 29 patients, admitted to University London College Hospital (UCLH) for unrelated reasons (Table S1) , who had confirmed B.1.1.7 infection. The majority (23/29) of these patients displayed relatively mild COVID-19 symptoms and a smaller number (6/29) remained COVID-19-asymptomatic. As antibody titres may depend on the severity of SARS-CoV-2 infection, as well as on time since infection, we compared B.1.1.7 sera with sera collected during the first wave of D614G variant spread in London from hospitalised COVID-19 patients 12 (n=20) and asymptomatic SARS-CoV-2-infected health care workers 13 (n=17) who were additionally sampled two months later.

IgG, IgM and IgA antibodies to the spikes of the Wuhan strain or of variants D614G, B.1.1.7 or B.1.351, expressed on HEK293T cells, were detected by a flow cytometry-based method (Fig. S1) 12 . Titres of antibodies that bound the parental D614G spike largely correlated with those that bound the B.1.1.7 or B.1.351 spikes (Fig. 1a-c) , consistent with the high degree of similarity. Similar correlations were observed for all three Ig classes also between the Wuhan strain and the three variant spikes and between the B.1.1.7 and B.1.351 spikes ( Fig. S2-S5 ).

Comparison of sera from acute D614G and B.1.1.7 infections revealed stronger recognition of the infecting variant than of other variants. Although B.1.1.7 sera were collected on average earlier than D614G sera (Table S1 ), titres of antibodies that bound the homotypic spike or neutralised the homotypic virus, as well as the relation between these two properties, were similar in D614G and B.1.1.7 sera (Fig. S6) , suggesting comparable immunogenicity of the two variants. Recognition of heterotypic spikes was reduced by a small, but statistically significant degree for both D614G and B.1.1.7 sera and for all three Ig classes ( Fig. 1d-f ). IgM or IgA antibodies in both D614G and B.1.1.7 sera were less cross-reactive than IgG antibodies (Fig. 1d-f ). The direction of cross-reactivity was disproportionally affected for some combinations, with IgA antibodies in D614G sera retaining on average 81% of recognition of the B.1.1.7 spike and IgA antibodies in B.1.1.7 sera retaining on average 30% of recognition of the D614G spike (Fig. 1f) . Similarly, recognition of the B.1.351 spike by IgM antibodies was retained, on average, to 71% in D614G sera and to 46% in B.1.1.7 sera (Fig. 1f) . Measurable reduction in polyclonal antibody binding to heterotypic spikes was unexpected, given >98% amino acid identity between them. However, reduction in serum antibody binding has also been observed for the receptor binding domain of the B.1.351 spike 4 . Together, these findings suggested that either the limited number of mutated epitopes were targeted by a substantial fraction of the response 7-10 or allosteric effects or conformational changes affecting a larger fraction of polyclonal antibodies.

To examine a functional consequence of reduced antibody recognition, we measured the half maximal inhibitory concentration (IC50) of D614G and B.1.1.7 sera using in vitro neutralisation of authentic Wuhan or B.1.1.7 and B.1.351 viral isolates ( Fig. 2a-b) . Titres of neutralising antibodies correlated most closely with levels of IgG biding antibodies for each variant (Fig. S5 ). Neutralisation of B.1.1.7 by D614G sera was largely preserved at levels similar to neutralisation of the parental Wuhan strain (fold change -1.3; range 3.0 to -3.8, p=0.183) (Fig. 2b) , consistent with other recent reports, where authentic virus neutralisation was tested 1, [7] [8] [9] 14 . Moreover, the ability of D614G sera to neutralise B.1.1.7 was preserved over time (Fig. S7) . Indeed, whilst binding antibody titres were significantly reduced for all three Ig classes in D614G sera in the two months of follow-up, neutralising antibody titres remained comparable for the Wuhan and B.1.1.7 strains and were undetectable at both time-points for the B.1.351 strain (Fig. S7) . Thus, D614G infection appeared to induce substantial and lasting crossneutralisation of the B.1.1.7 variant. However, the reverse was not true. Neutralisation of the parental Wuhan strain by B.1.1.7 sera was significantly reduced, compared to neutralisation of the infecting B.1.1.7 variant (fold change -3.4; range -1.20 to -10.6, p<0.001) (Fig. 2b) , and the difference in crossneutralisation drop was also significant (p<0.001). Both D614G and B.1.1.7 sera displayed significantly reduced neutralisation of the B.1.351 variant with a fold change of -8.2 (range -1.7 to -33.5) and -7.7 (range -3.4 to -17.9), respectively (Fig. 2b) .

Together, these results argue that natural infection with each SARS-CoV-2 strain induces antibodies that recognise the infecting strain most strongly, with variable degrees of cross-recognition of the other strains. Importantly, antibodies induced by B.1.1.7 infection were less cross-reactive with other dominant SARS-CoV-2 strains than those induced by the parental strain. Similar findings were recently obtained independently with a small number of B.1.1.7 convalescent sera 14 . This unidirectional pattern of cross-reactivity argues that emergence of B.1.1.7 is unlikely to have been driven by antibody escape. 

Serum or plasma samples from D614G infection were obtained from University College London Hospitals (UCLH) (REC ref: 20/HRA/2505) COVID-19 patients (n=20, acute D614G infection, COVID-19 patients) as previously described 12 , or from UCLH health care workers (n=17, acute D614G infection, mild/asymptomatic), as previously described 13 (Table S1 ). These samples were collected between March 2020 and June 2020. Serum or plasma samples from B.1.1.7 infection were obtained from patients (n=29, acute B.1.1.7 infection, mild/asymptomatic) admitted to UCLH (REC ref: 20/HRA/2505) for unrelated reasons, between December 2020 and January 2021, who then tested positive for SARS-CoV-2 infection by RT-qPCR, as part of routine testing (Table S1 ). Infection with B.1.1.7 was confirmed by sequencing of viral RNA, covered from nasopharyngeal swabs. A majority of these patients (n=23) subsequently developed mild COVID-19 symptoms and 6 remained asymptomatic. All serum or plasma samples were heat-treated at 56 o C for 30 min prior to testing.

SARS-CoV-2 nucleic acids were detected in nasopharyngeal swabs from hospitalised patients by a diagnostic RT-qPCR assay using custom primers and probes 16 , Assays were run by Health Services Laboratories (HSL), London, UK. Diagnostic RT-qPCR assays for SARS-CoV-2 infection in health care workers was run at the Francis Crick Institute, as previously described 17 . SARS-CoV-2 RNA-positive samples (RNA amplified by Aptima Hologic) were subjected to real-time whole-genome sequencing at the UCLH Advanced Pathogen Diagnostics Unit. RNA was extracted from nasopharyngeal swab samples on the QiaSymphony platform using the Virus Pathogen Mini Kit (Qiagen). Libraries were prepared using the Illumina DNA Flex library preparation kit and sequenced on an Illumina MiSeq (V2) using the ARTIC protocol for targeted amplification (primer set V3). Genomes were assembled using an in-house pipeline 18 and aligned to a selection of publicly available SARS-CoV-2 genomes 19 using the MAFFT alignment software 20 . Phylogenetic trees were generated from multiple sequence alignments using IQ-TREE 21 and FigTree (http://tree.bio.ed.ac.uk/software/figtree), with lineages assigned (including B.1.1.7 calls) using pangolin (http://github.com/cov-lineages/pangolin), and confirmed by manual inspection of alignments. (D614G, L18F, D80A, D215G, Δ242-244, R246I, K417N, E484K, N501Y, A701V) (both synthesised and cloned by GenScript). All transfections were carried out using GeneJuice (EMD Millipore) and transfection efficiency was between 20% and 54% in separate experiments.

The SARS-CoV-2 reference isolate (referred to as the Wuhan strain) was the hCoV-19/England/02/2020, obtained from the Respiratory Virus Unit, Public Health England, UK, (GISAID EpiCov TM accession EPI_ISL_407073). The B.1.1.7 isolate was the hCoV-19/England/204690005/2020, which carries the D614G, Δ69-70, Δ144, N501Y, A570D, P681H, T716I, S982A and D1118H mutations 14 , obtained from Public Health England (PHE), UK, through Prof. Wendy Barclay, Imperial College London, London, UK. The B.1.351 virus isolate was the 501Y.V2.HV001, which carries the D614G, L18F, D80A, D215G, Δ242-244, K417N, E484K, N501Y, A701V mutations 3 . However, sequencing of viral genomes isolated following further passage in Vero V1 cells identified the Q677H and R682W mutations at the furin cleavage site, in approximately 50% of the genomes. All viral isolates were propagated in Vero V1 cells.

HEK293T cells were transfected to express the different SARS-CoV-2 spike variants. Two days after transfection, cells were trypsinized and transferred into V-bottom 96-well plates (20,000 cells/well). Cells were incubated with sera (diluted 1:50 in PBS) for 30 min, washed with FACS buffer (PBS, 5% BSA, 0.05% sodium azide), and stained with BV421 anti-IgG (clone HP6017, Biolegend), APC anti-IgM (clone MHM-88, Biolegend) and PE anti-IgA (clone IS11-8E10, Miltenyi Biotech) for 30 min (all antibodies diluted 1:200 in FACS buffer). Cells were washed with FACS buffer and fixed for 20 min in CellFIX buffer (BD Bioscience). Samples were run on a Ze5 analyzer (Bio-Rad) running Bio-Rad Everest software v2.4 or an LSR Fortessa with a high-throughput sampler (BD Biosciences) running BD FACSDiva software v8.0, and analyzed using FlowJo v10 (Tree Star Inc.) analysis software, as previously described 12 . All runs included 3 positive control samples, which were used for normalisation of mean fluorescence intensity (MFI) values. To this end, the MFI of the positively stained cells in each sample was expressed as a percentage of the MFI of the positive control on the same 96-well plate.

SARS-CoV-2 variant neutralisation was tested using an in-house developed method (Fig. S8) . Heatinactivated serum samples in QR coded vials (FluidX/Brooks) were assembled into 96-well racks along with foetal calf serum-containing vials as negative controls and SARS-CoV-2 spike RBD-binding nanobody (produced in-house) vials as positive controls. A Viaflo automatic pipettor fitted with a 96channel head (Integra) was used to transfer serum samples into V-bottom 96-well plates (Thermo 249946) prefilled with Dulbecco's Modified Eagle Medium (DMEM) to achieve a 1:10 dilution. The Viaflo was then used to serially dilute from the first dilution plate into 3 further plates at 1:4 to achieve 1:40, 1:160, and 1:640. Next, the diluted serum plates were stamped into duplicate 384-well imaging plates (Greiner 781091) pre-seeded the day before with 3,000 Vero E6 cells per well, with each of the 4 dilutions into a different quadrant of the final assay plates to achieve a final working dilution of samples at 1:40, 1:160, 1:640, and 1:2560. Assay plates were then transferred to containment level 3 (CL3) where cells were infected with the indicated SARS-CoV-2 viral strain, by adding a pre-determined dilution of the virus prep using a Viaflo fitted with a 384 head with tips for the no-virus wells removed. Plates were incubated for 24 hours at 37 o C, 5% CO2 and then fixed by adding a concentrated formaldehyde solution to achieve a final concentration of 4%. Assay plates were then transferred out of CL3 and fixing solution washed off, cells blocked and permeabilised with a 3% BSA/0.2% Triton-X100/PBS solution, and finally immunostained with DAPI and a 488-conjugated anti-nucleoprotein monoclonal antibody (produced in-house). Automated imaging was carried out using an Opera Phenix (Perkin Elmer) with a 5x lens and the ratio of infected area (488-positive region) to cell area (DAPIpositive region) per well calculated by the Phenix-associated software Harmony. A custom automated script runs plate normalisation by background subtracting the median of the no-virus wells and then dividing by the median of the virus-only wells before using a 3-parameter dose-response model for curve fitting and identification of the dilution which achieves 50% neutralisation for that particular serum sample (IC50).

Data were analysed and plotted in SigmaPlot v14.0 (Systat Software). Parametric comparisons of normally-distributed values that satisfied the variance criteria were made by paired or unpaired Student's t-tests or One Way Analysis of variance (ANOVA) tests. Data that did not pass the variance test were compared with Wilcoxon Signed Rank Tests. 1 Seroconversion and/or first positive RT-qPCR in the first month of enrolment (month 1). The same group of participants were samples again 2 months later (month 3). 

Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies. bioRxiv

SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma. bioRxiv

Escape of SARS-CoV-2 501Y.V2 variants from neutralization by convalescent plasma. medRxiv

Reduced binding and neutralization of infection-and vaccine-induced antibodies to the B.1.351 (South African) SARS-CoV-2 variant. bioRxiv

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2

Neutralizing Activity of BNT162b2-Elicited Serum -Preliminary Report

Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7. bioRxiv

SARS-CoV-2 variants show resistance to neutralization by many monoclonal and serum-derived polyclonal antibodies

Vaccine-induced immunity provides more robust heterotypic immunity than natural infection to emerging SARS-CoV-2 variants of concern

Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine induced sera

New variant of SARS-CoV-2 in UK causes surge of COVID-19

Preexisting and de novo humoral immunity to SARS-CoV-2 in humans

Pandemic peak SARS-CoV-2 infection and seroconversion rates in London frontline health-care workers

Increased transmission of SARS-CoV-2 lineage B.1.1.7 (VOC 2020212/01) is not accounted for by a replicative advantage in primary airway cells or antibody escape. bioRxiv

Adaptive immunity to SARS-CoV-2 and COVID-19

Extraction-free COVID-19 (SARS-CoV-2) diagnosis by RT-PCR to increase capacity for national testing programmes during a pandemic. bioRxiv

Scalable and robust SARS-CoV-2 testing in an academic center

Emergence of a novel subclade of influenza A(H3N2) virus in London

Data, disease and diplomacy: GISAID's innovative contribution to global health

MAFFT multiple sequence alignment software version 7: improvements in performance and usability

IQ-TREE: a fast and effective stochastic algorithm for estimating maximum-likelihood phylogenies

We are grateful for assistance from the Flow Cytometry and Cell Services facilities at the Francis Crick Institute and to Mr Michael Bennet and Mr Simon Caidan for training and support in the highcontainment laboratory. We wish to thank the Public Health England (PHE) Virology Consortium and PHE field staff, the ATACCC (Assessment of Transmission and Contagiousness of COVID-19 in Contacts) investigators, the G2P-UK (Genotype to Phenotype-UK) National Virology Consortium, and Prof Wendy Barclay, Imperial College London, London, UK, for the B.1.1.7 viral isolate. This work was supported by the Francis Crick Institute, which receives its core funding from Cancer Research UK, the UK Medical Research Council, and the Wellcome Trust. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

 Figure S8 . SARS-CoV-2 neutralisation assay set up. 96-well racks of serum samples including controls are serially diluted after an initial dilution of 1:10 to generate 4 total dilution plates. These are used to treat pre-seeded Vero E6 cells in 384-well assay plates in duplicate before infection with SARS-CoV-2 virus. After immunostaining with DAPI and a 488-conjugated monoclonal antibody against SARS-CoV-